Evidence map›Paper›PMID 36354459›Full record

ArticleBiosensors2022

Aptamer-Gated Mesoporous Silica Nanoparticles for N Protein Triggered Release of Remdesivir and Treatment of Novel Coronavirus (2019-nCoV).

Xiaohui Zhang, Xin Zhang, Aoqiong Xu, Mengdi Yu, Yu Xu, Ying Xu, Chao Wang, Gege Yang, Chunxia Song, Xiangwei Wu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Xiaohui ZhangDepartment of Applied Chemistry, Anhui Agricultural University, Hefei 230036, China.
Xin ZhangDepartment of Applied Chemistry, Anhui Agricultural University, Hefei 230036, China.
Aoqiong XuDepartment of Applied Chemistry, Anhui Agricultural University, Hefei 230036, China.
Mengdi YuDepartment of Applied Chemistry, Anhui Agricultural University, Hefei 230036, China.
Yu XuDepartment of Applied Chemistry, Anhui Agricultural University, Hefei 230036, China.
Ying XuDepartment of Applied Chemistry, Anhui Agricultural University, Hefei 230036, China.
Chao WangDepartment of Applied Chemistry, Anhui Agricultural University, Hefei 230036, China.
Gege YangDepartment of Applied Chemistry, Anhui Agricultural University, Hefei 230036, China.
Chunxia SongDepartment of Applied Chemistry, Anhui Agricultural University, Hefei 230036, China.
Xiangwei WuKey Laboratory of Agri-Food Safety of Anhui Province, College of Resources and Environment, Anhui Agricultural University, Hefei 230036, China.
Ying LuDepartment of Applied Chemistry, Anhui Agricultural University, Hefei 230036, China.
Anhui Agricultural University · CNMinistry of Agriculture and Rural Affairs · CN

Funding

Natural Science Foundation of Education Committee of Anhui Province KJ2021A0176NSFC of China 21305002NSFC of China 21705002
6 · The paper itself

Abstract

Since the 2019-nCoV outbreak was first reported, hundreds of millions of people all over the world have been infected. There is no doubt that improving the cure rate of 2019-nCoV is one of the most effective means to deal with the current serious epidemic. At present, Remdesivir (RDV) has been clinically proven to be effective in the treatment of SARS-CoV-2. However, the uncertain side effects make it important to reduce the use of drugs while ensuring the self-healing effect. We report an approach here with targeted therapy for the treatment of SARS-CoV-2 and other coronaviruses illness. In this study, mesoporous silica was used as the carrier of RDV, the nucleocapsid protein (N protein) aptamer was hybridized with the complementary chain, and the double-stranded DNA was combined with gold nanoparticles as the gates of mesoporous silica pores. When the RDV-loaded mesoporous silica is incubated with the N protein, aptamer with gold nanoparticles dissociate from the complementary DNA oligonucleotide on the mesoporous silica surface and bind to the N protein. The releasing of RDV was determined by detecting the UV-vis absorption peak of RDV in the solution. These results show that the RDV delivery system designed in this work has potential clinical application for the treatment of 2019-nCoV.

Indexed as

Aptamers, NucleotideCOVID-19 Drug TreatmentMetal NanoparticlesNanoparticlesAdenosine MonophosphateAlanineGoldHumansSARS-CoV-2Silicon DioxideAdenosine MonophosphateAlanineAptamers, NucleotideGoldremdesivirSilicon Dioxide2019-nCoVaptamermesoporous silicaRemdesivirtargeted therapy

Identifiers

PMID36354459
PMCPMC9688528
OpenAlexW4307923038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.